Microarray Market Size, Share & Trends Analysis Report By Product And Services (Instruments, Consumables), By Type, By Application (Drug Discovery, Disease Diagnostics), By End-use, By Region, And Segment Forecasts

Published Date: May - 2025 | Publisher: MIR | No of Pages: 240 | Industry: healthcare | Format: Report available in PDF / Excel Format

View Details Buy Now 2999 Download Sample Ask for Discount Request Customization

Microarray Market Size & Trends

The worldwide microarray market size was estimated to be approximately USD 6.22 billion by 2024 and is further expected to grow at a CAGR of 5.48% during the period of 2025 to 2030. Microarrays have been in the limelight due to their application for high-throughput genetic screening and molecular profiling for cancer studies, genetic diseases, and infectious disease diagnosis. Owing to greater technological innovations, the surge in demand for genetic analysis, and greater investment in research and development, the global microarray infrastructure will increase at a remarkable rate during the forecast period.

Personalized medicine is also one of the factors, as researchers can employ these instruments to determine specific disease markers, making it possible to have targeted therapies. Microarrays in diagnostics, forensic science, and agricultural biotechnology have also reinforced the growth of the market. The growing focus on early disease detection and preventive care will fuel market growth. Microarrays assist scientists and clinicians in identifying early indications of biomarkers for several ailments, enabling them to intervene early to enhance patient results. Early detection is key in oncology, where microarrays can diagnose the genes that are behind tumor growth, making preventive and individualized interventions possible.

Increasing funding and research in the microarray patch platform will propel market growth. In March 2023, Vaxess Technologies revealed that it raised an additional USD 9 million in funding to help develop its MIMIX sustained-release intradermal microarray patch platform. The platform aims to revolutionize the delivery of vaccines and therapeutics by facilitating sustained-release dosing via a simple, self-administered patch. The round was supported by both current and new investors such as RA Capital Management and The Engine. The funds raised will be used to further multiple programs, among them influenza and COVID-19 vaccines, as well as further extend applications of its microarray technology into other therapeutic areas.

Microarrays are powerful tools to study the plant genome and increase productivity by identifying the genetic traits that defend against pathogens and climatic alterations. Furthermore, globally, food security has become a serious issue; microarrays supply crucial information regarding transgenic alterations and agricultural improvements. In environmental science, they are employed to measure the impact of pollutants on patterns of gene expression in living organisms, thus enhancing sustainability programs and eco-conservation efforts. Hence, the broad applicability of microarray technology across various disciplines is another factor propelling product demand.

Microarray-based diagnostic tests are now revolutionary tools in the detection and management of connective tissue diseases (CTDs) like systemic lupus erythematosus (SLE), systemic sclerosis, Sjögren's syndrome, mixed connective tissue disease, and polymyositis/dermatomyositis. Overlapping symptoms are a hallmark of these disabling autoimmune disorders, and hence early and accurate diagnosis is challenging. Microarrays are a high-throughput and accurate solution for this diagnostic challenge. For example, in May 2022, Theradiag and Quotient Limited announced a collaboration to develop a diagnostic test for connective tissue diseases using microarray-based testing. The collaboration is set to utilize Theradiag's experience in autoimmune diagnostics and Quotient's expertise in multiplex testing to develop an advanced diagnostic solution.

Market Concentration & Characteristics

The market is characterized by rapidly escalating innovation, fueled by ongoing improvements in genomics, proteomics, and personalized medicine. Firms are making more investments in the creation of high-throughput platforms, multiplex assays, and AI-based data analytics tools that improve the accuracy and speed of diagnostics and research. The shift towards next-generation microarray platforms, including those supporting simultaneous detection of hundreds of biomarkers, further characterizes the market's innovative environment. In August 2023, Thermo Fisher Scientific launched the Applied Biosystems CytoScan HD Accel array, a chromosomal microarray that has been developed to increase cytogenetic research productivity. The array provides a turnaround time of two days and greater coverage of more than 5,000 essential genomic regions. It takes 50% or less DNA input than other arrays and can accept a broad array of sample types, such as buccal swabs, saliva, and blood. This innovation responds to the increasing need for effective laboratory services in the face of a shortage of qualified experts. Additionally, the application of microarrays to drug discovery pipelines, disease screening, and immunological profiling enhances innovation in clinical and translational research.

The sector is characterized by high activity in mergers and acquisitions (M&A), with key players aiming to expand their technological expertise, strengthen their product portfolios, and venture into new geographic markets. Strategic M&A purchases are also being used to obtain proprietary microarray platforms, bioinformatics software, and complementary diagnostic technologies. These transactions tend to accelerate innovation cycles, shorten development timelines, and consolidate market position. Notable M&A trends also include biotech startups joining forces with or being acquired by incumbent diagnostics leaders to increase manufacturing scale and broaden their commercial reach.

The market is under intense regulatory oversight, especially in the U.S. and Europe, where FDA and CE clearances are essential for commercialization. Regulations cut across several areas such as test validation, reproducibility of data, clinical precision, and patient safety. Regulational frameworks are particularly strict on clinical diagnostics with genetic information and autoimmune disease diagnosis where multiplex assays have to go through intensive performance assessment. Although this can be an entry barrier, it also fuels quality assurance, standardization, and trust in clinical use, further spurring innovation to regulatory expectations.

Product development within the industry is high, fueled by growing demand for precision diagnostics, targeted treatments, and population-scale screening programs. Firms are proactively launching new product formats, including integrated lab-on-chip microarrays, high-density arrays, and user-defined panels for particular diseases like cancer, autoimmune diseases, and infectious diseases. Moreover, the development of portable microarray devices for point-of-care testing and the growth of microarray-based research kits across academic and pharmaceutical institutions are facilitating increased market penetration. This dynamic product diversification also keeps enhancing the competitive position and addressing changing end-user requirements. 

The industry is experiencing a medium to high extent of regional expansion as companies focus on realizing opportunities in rising economies while securing bases in developed geographies. The Asia-Pacific region, Latin America, and the Middle East are emerging as key targets given improving healthcare investment, rising healthcare expenditure awareness on diagnostic testing, and developing healthcare infrastructure. Market leaders are establishing local manufacturing facilities, forging partnerships with local distributors, and tailoring product offerings to local market needs. Yet regional growth initiatives are frequently faced with the challenges of different regulatory regimes and barriers to market access, necessitating differentiated approaches by geography.

Product And Services Insights

Consumables dominated the market share of 49.73% in 2024. This is mainly due to the repeated requirement of assay kits, slides, and reagents utilized in different experiments, which are required across genomics, proteomics, and clinical diagnostic applications. The increasing application of gene expression analysis and SNP genotyping has immensely boosted the quantity of consumables usage in academic research as well as commercial laboratories. Emerging developments in nanotechnology have also made it possible to produce high-density microarray chips, enhancing test accuracy and minimizing assay time, further driving demand. In addition, the availability of user-defined microarray platforms has made it possible to pursue focused research and personalized diagnosis. Recently, in February 2024, axiV. This collaboration enhances axiVEND’s offerings by adding PolyAn’s range of functionalized slides, coverslips, plates, and custom solutions to its existing portfolio, which includes M2-Automation spotters and Bioscience Media microarray imagers.

Instruments are expected to grow at the fastest rate over the forecast period, driven by the increasing demand for automation, precision, and scalability in molecular diagnostics and research applications. These devices consist of microarray scanners, hybridization stations, and robotic handling systems, which together increase throughput and reduce human error. Advances in technology have led to next-generation platforms with real-time data acquisition, enhanced signal resolution, and compatibility with a wider variety of microarray formats. One such advancement is integration with cloud-based data analytics, allowing researchers and clinicians to process large datasets effectively.

Type Insights

DNA microarrays accounted for the largest revenue share in 2024. The utility of DNA microarrays in identifying disease biomarkers and enabling pharmacogenomic insights continues to drive their adoption in both clinical diagnostics and translational research. Technological enhancements, such as improved probe design and higher array density, have made the platforms more sensitive and cost-effective. Recently, companies like Thermo Fisher and Agilent have introduced updated microarray formats with improved detection capabilities for rare mutations, further enhancing clinical relevance. The use of DNA microarrays is expanding in population health programs and cancer genomics, creating strong opportunities for growth in regions focusing on personalized medicine. In August 2023, Thermo Fisher Scientific introduced two advanced genomic tools aimed at enhancing research capabilities in cytogenetics and population-scale studies. The Applied Biosystems CytoScan HD Accel array offers a comprehensive analysis of the human genome, providing improved coverage in over 5,000 critical genome regions. This array is designed to support a wide range of prenatal, postnatal, and oncology research applications, delivering results with an industry-leading two-day turnaround time. Its efficiency is particularly beneficial for laboratories facing increased demand and a shortage of trained professionals, enabling up to a 100% increase in assay productivity using existing equipment.

Protein microarrays are expected to grow at the fastest rate over the forecast period, owing to their increasing use in drug discovery, immune profiling, and biomarker validation. Unlike DNA microarrays, protein arrays enable the simultaneous analysis of multiple protein interactions, making them indispensable in proteomics research. The rising prevalence of autoimmune and infectious diseases has created demand for rapid, multiplexed diagnostics that protein microarrays can support effectively. Recent developments include the introduction of label-free detection systems and miniaturized formats that reduce sample volumes while maintaining assay sensitivity. Companies like RayBiotech and Arrayit have expanded their product lines to support applications in cytokine profiling, antibody specificity testing, and allergen screening.

Application Insights

The research applications segment led the microarray market in 2024, driven by growing investments in genomics, proteomics, and biomedical research. Microarrays are essential instruments to comprehend gene function, discover new disease mechanisms, and identify novel drug targets. Government-funded initiatives such as the U.S. NIH's All of Us program and the EU's Horizon Europe program have fueled demand for microarray-based research, especially in population genomics and biomarker discovery. Recent years have seen research institutes reap the rewards of new multiplexing technologies that enable the high-throughput analysis of higher accuracy. Furthermore, in January 2024, Thermo Fisher introduced the Axiom PangenomiX Array, its most ethnically diverse and inclusive array to date. This all-in-one, high-throughput microarray integrates four testsSNP genotyping, whole genome copy number variant identification, fixed copy number discovery, and blood and HLA typing into one test. It is intended to further disease risk and detection research, population-scale disease research, ancestry and wellness testing, drug efficacy testing, and drug discovery.

The segment for disease diagnostics is expected to expand at the highest rate during the forecast period. Microarray-based diagnostics have high specificity and multiplexing ability, enabling the simultaneous measurement of numerous biomarkers, making them well suited for complex disease profiling. Developments in chromosomal microarray analysis (CMA) for the detection of developmental delay, congenital malformations, and neurological disorders have placed microarrays at the center stage in clinical genomics. The most recent development is the introduction of Thermo Fisher's two-day turnaround chromosomal microarray, which greatly improves lab efficiency. Concurrently, FDA 510(k) clearances such as AliveDx's CTDPlus multiplex microarray test illustrate the increased clinical acceptance of these platforms.

End-use Insights

Research and academic institutes accounted for the largest revenue share of the market in 2024. Universities and publicly funded research centers are key users of microarray platforms for genomics, transcriptomics, and proteomics investigations. Moreover, many institutes have established core facilities to offer centralized access to microarray technologies, promoting interdisciplinary research. Collaborations between academia and commercial vendors like Agilent and PerkinElmer have led to the co-development of specialized arrays for niche applications, such as rare disease gene panels or epigenetic studies.

The diagnostic laboratories segment is expected to grow at the fastest CAGR during the forecast period. This growth is largely driven by the increasing adoption of molecular diagnostics for disease screening, stratification, and monitoring. Labs are turning to microarrays due to their ability to process multiple patient samples in parallel, deliver quick results, and reduce testing costs through multiplexing. Recent developments include the expansion of CLIA-certified labs in the U.S. and Europe, offering microarray-based tests for prenatal screening, autoimmune diseases, and cancer genetics. Companies like Arrayit Corporation and Bio-Rad have launched compact platforms designed specifically for clinical lab settings, enabling streamlined workflows and higher throughput.

Regional Insights

Market Analysis

North America microarray market led the world and held a 48.27% share in 2024. The market growth in the region is due to the availability of research institutes, pharmaceutical, and biotechnology firms, which have driven the demand for microarrays in the region. The widespread adoption of emerging technologies, including next-generation sequencing, and increasing investment in research and development activities, especially in the U.S., have further fueled the expansion of the microarray market in North America. Moreover, favorable government policies enabling research and development, as well as the presence of a long-established healthcare base in the region, have driven the market favorably, pushing North America into the largest contributory position on the global level.

U.S. Microarray Market Trends
The U.S. microarray market is sustained by heavy investment in R&D, a thoroughly established academic as well as clinical research base, and robust funds support from players such as the National Institutes of Health (NIH). The application of microarrays in genomic research, cancer diagnostics, and pharmacogenomics is picking up pace, particularly in personalized medicine. Recent developments have involved collaborations between academic centers and biotech firms to drive high-density DNA microarrays and protein microarrays. In addition, the presence of key players like Thermo Fisher Scientific and Agilent Technologies guarantees innovation in microarray platforms and consumables. In April 2025, AliveDx reported that it had filed a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) for its MosaiQ Autoimmune Plex (AIPlex) Connective Tissue Diseases (CTDplus) Multiplex Microarray. The AIPlex CTDplus microarray is intended to assist in the diagnosis of autoimmune connective tissue diseases by multiplex detection of several biomarkers from a single patient sample. This points to a shift toward multiplex, high-throughput microarray platforms—technologies that align with the U.S. healthcare market's emphasis on precision medicine, cost-efficient testing, and better patient outcomes.

Europe Microarray Market Trends
The European microarray market is fast growing, underpinned by strong expansion in genomics research and a rising need for precision medicine. Germany, France, and the Netherlands are at the forefront of microarray technology adoption for academic and clinical applications. A key market driver is the European Union's investment in large-scale genomic initiatives and healthcare digitization. Microarrays have been increasingly used by research institutions in Europe over the past few years for applications like transcriptomics and biomarker discovery. Regulatory harmonization and a focus on data privacy under GDPR have promoted responsible innovation. Businesses in the region are entering into partnerships to localize supply chains and manufacturing. Additionally, the application of microarrays in agricultural genomics and environmental monitoring is picking up pace.

The UK microarray market is growing strongly, led by government-funded programs such as Genomics England and the 100,000 Genomes Project. These have established a solid foundation in microarray-based research tools and diagnostics. The expanded emphasis on diagnosis of rare disease and personalized cancer treatment has driven gene expression and SNP array use. Developments in recent times include public-private partnerships to further develop translational research capabilities and increase production capacity for next-generation microarray systems. Universities and research centers affiliated with the NHS are among the leading users of microarray technologies for clinical research and validation studies.

The German microarray market is on the rise. Demand for microarrays is especially high in oncology, infectious disease diagnosis, and pharmacogenetics. One driving force behind the growth is national emphasis on digital health and precision diagnostics, promoting the integration of genomic information into the delivery of healthcare. Some of the recent innovations involve joint efforts between German academia and private sector companies to enhance the sensitivity and specificity of microarray assays. Of particular importance has been funding by the government of Germany to high-throughput molecular diagnostic platforms.

Asia Pacific Microarray Market Trends

The microarray market in Asia Pacific is anticipated to witness significant growth, driven by the increasing investment in research and development activities, particularly in countries such as China, Japan, and South Korea, which are rapidly emerging as hubs for biotechnology and pharmaceutical research. Additionally, the growing demand for personalized medicine, rising healthcare expenditure, and improving research infrastructure in the region will further fuel the growth of the microarray market in the Asia Pacific, making it an attractive destination for market players.

China microarray market held a substantial share in 2023 due to the country's significant investments in genomics and precision medicine initiatives, such as the China Precision Medicine Initiative, which has driven the adoption of microarray technology in research and diagnostic applications. Additionally, China's large patient population, growing biotechnology industry, and increasing government support for research and development activities have further fueled the industry expansion.

The Japanese market for microarrays is growing steadily, supported by its well-established healthcare system, strong R&D intensity, and emphasis on advanced diagnostics. The nation has been an early adopter of microarray technologies for research and clinical diagnostics, especially in cancer genomics, pharmacogenetics, and screening for rare diseases. Some of the driving factors are the aging population and government initiatives towards precision medicine with initiatives like the Japan Agency for Medical Research and Development (AMED). Recent advances include the combination of microarray data with AI technologies to tailor treatment suggestions, and a number of local companies are developing next-generation array formats with improved processing speeds.

Latin America Microarray Market Trends

The microarray market in Latin America is gradually expanding, primarily driven by improvements in healthcare access, rising interest in genomics, and the growing incidence of chronic diseases. Countries such as Argentina are increasingly investing in molecular diagnostics, where microarrays play a critical role. One of the key drivers is the increasing demand for affordable genetic screening tools for oncology and infectious diseases. Recent developments include pilot genomics programs and partnerships between public health institutes and academic centers to build local sequencing and microarray capabilities.

Brazil microarray market is witnessing substantial growth, fueled by increasing healthcare investments and the national focus on biotechnology development. The country has been advancing in genomic research through institutions like Fiocruz and the University of São Paulo. Key drivers include the rising prevalence of cancer, rare genetic disorders, and the need for efficient diagnostic tools in public health. The market is seeing increased adoption of DNA and protein microarrays in both clinical and agricultural applications. Recent developments include partnerships between domestic companies and global diagnostics providers to localize production and reduce costs.

Middle East & Africa Microarray Market Trends

The microarray market in the Middle East & Africa is in a nascent but promising stage, supported by growing investment in healthcare infrastructure and interest in genomics. Countries such as the UAE and South Africa are leading adoption, particularly for oncology diagnostics and infectious disease screening. A major driver is the region’s increasing burden of chronic and hereditary diseases, necessitating advanced diagnostic tools. Recently, in May 2023, Thermo Fisher Scientific and the Qatar Genome Program (QGP) announced a collaboration to develop a custom Axiom genotyping array tailored for pan-Arab populations. Utilizing whole genome sequencing data from 19 Arab countries, the array comprises approximately 800,000 variants. This initiative aims to advance research into conditions such as diabetes, cardiovascular diseases, autism, inherited genetic disorders, and cancer. The array is intended to provide a cost-effective alternative to whole-genome sequencing, thereby facilitating increased diversity in large-scale genome-wide studies.

Saudi Arabia microarray market is experiencing robust growth. The government’s support for digital health transformation and partnerships with international biotechnology firms are key market drivers. Recent developments include the establishment of national genomics initiatives and collaborations with universities to expand genetic testing capabilities. The Saudi Center for Disease Prevention and Control has shown interest in using microarrays for surveillance and outbreak monitoring.

Key Microarray Company Insights

Some of the prominent players in the microarray and microarray market are Thermo Fisher Scientific Inc (Applied Biosystems), Agilent Technologies, Inc., Illumina, Inc., PerkinElmer, Merck KGaA, Schott (Applied Microarrays), Danaher Corporation, Arrayit Corporation, Bio-Rad Laboratories, Inc., and Microarrays Inc. These established companies use strong R&D strengths, cutting-edge technological infrastructure, and international distribution networks to drive innovation in genetic testing, precision medicine, and molecular diagnostics. Their strategic priorities involve ongoing product innovation, grand-scale partnerships, and mergers & acquisitions for the purposes of building product portfolios and expanding market presence.

New entrants in the market, including Arrayjet, Sengenics, Alere Technologies (Abbott), and Creative Biolabs, are more interested in differentiated products to enter niche segments. These players are more interested in innovation through high-throughput platforms, multiplex assays, and low-cost diagnostic tools. Through collaborations with academic institutions, biotech companies, and government agencies, these new entrants seek to increase their geographic reach, access underserved markets, and drive the adoption of advanced microarray technologies in diagnostics and biomedical research.

Key Microarray Companies

The following are the leading companies in the microarray market. These companies collectively hold the largest market share and dictate industry trends.

Recent Developments

  • In February 2025, PathogenDx launched its rebranded D3 Array assays, including Combined, Bacterial, and Fungal versions, to replace its previous DetectX line. The D3 Array technology enables multiplex detection of up to 100 targets in a single test, offering rapid, cost-effective, and high-throughput solutions for agriculture, food safety, environmental, and clinical testing. The assays provide both quantitative and qualitative results with high sensitivity and specificity, enhancing laboratory efficiency and return on investment.

  • LinkZill announced the launch of its TruArray Std 4K High-Throughput Oligonucleotide Microarray Chip, based on TFT-DNA synthesis technology. The chip achieves high coverage and uniformity, with oligonucleotide lengths up to 150 nucleotides. It offers a balance of high throughput, accuracy, and cost-effectiveness, catering to various applications in genomics research.

  • In August 2024, Illumina, Inc. announced the launch of its NovaSeqX series, a new line of sequencing systems that promises to deliver faster, more cost-effective genomic sequencing. The NovaSeqX series features enhanced performance and scalability, aimed at accelerating research and improving data accessibility for a range of applications. This advancement supports comprehensive genetic studies and facilitates personalized medicine and genomics breakthroughs.

  • In January 2024, Thermo Fisher Scientific introduced the Pangenomix Array, a new genomic tool designed to enhance the study of genetic variations across diverse populations. This advanced array provides comprehensive coverage of human genetic diversity, facilitating more accurate genetic research and personalized medicine.

  • In August 2023, Thermo Fisher Scientific introduced the Applied Biosystems CytoScan HD Accel array, a chromosomal microarray designed to enhance cytogenetic research productivity. The array offers a two-day turnaround time and improved coverage across over 5,000 critical genomic regions. It requires up to 50% less DNA input compared to other arrays and supports a wide range of sample types, including buccal swabs, saliva, and blood. This innovation addresses the growing demand for efficient laboratory services amid a shortage of trained professionals. 

Microarray Market Report Scope

Report Attribute

Details

Market size value in 2025

USD 6.48 billion

Revenue forecast in 2030

USD 8.46 billion

Growth rate

CAGR of 5.48% from 2025 to 2035

Actual data

2018 - 2024

Forecast period

2025 - 2035

Quantitative units

Revenue in USD million/billion, and CAGR from 2025 to 2035

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product & services, type, application, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico; UK; Germany; France; Spain; Italy; Sweden; Denmark; Sweden; Norway; Japan; China; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Thermo Fisher Scientific Inc. (Applied Biosystems); Agilent Technologies, Inc.; Illumina, Inc.; PerkinElmer; Merck KGaA; Schott (Applied Microarrays); Danaher Corporation; Arrayit Corporation; Bio-Rad Laboratories; Inc.; and Microarrays Inc.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Microarray Market Report Segmentation

Product & services Outlook (Revenue, USD Million, 2018 - 2035)

    • Consumables

    • Software and Services

    • Instruments

  • Type Outlook (Revenue, USD Million, 2018 - 2035)

    • DNA Microarrays

    • Protein Microarrays

    • Other Microarrays

  • Application Outlook (Revenue, USD Million, 2018 - 2035)

    • Research Applications

    • Drug Discovery

    • Disease Diagnostics

    • Other Applications

  • End-use Outlook (Revenue, USD Million, 2018 - 2035)

    • Research & Academic Institutes

    • Pharmaceutical & Biotechnology Companies

    • Diagnostic Laboratories

    • Other End Users

  • Regional Outlook (Revenue, USD Billion, 2018 - 2035)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • UK

      • Germany

      • France

      • Spain

      • Italy

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Related Reports

Table of Content

List Tables Figures

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email